RESUMEN
The coronavirus disease 2019 (COVID-19) pandemic can lead to a severe course of disease in immunosuppressed patients requiring intensive care unit treatment even though a number of new vaccines and new antiviral drugs exist. One of the main reasons for this is the generally poorer immune response under immunosuppression. Therefore, it is all the more important to know the stages of the disease and to select the currently available therapeutic options accordingly.Copyright © 2023, The Author(s), under exclusive licence to Springer Medizin Verlag GmbH, ein Teil von Springer Nature.
RESUMEN
The coronavirus disease 2019 (COVID-19) pandemic can lead to a severe course of disease in immunosuppressed patients requiring intensive care unit treatment even though a number of new vaccines and new antiviral drugs exist. One of the main reasons for this is the generally poorer immune response under immunosuppression. Therefore, it is all the more important to know the stages of the disease and to select the currently available therapeutic options accordingly.
RESUMEN
The PCR-test for SARS-CoV-2 represents the state of the art in diagnosing COVID-19 disease as at November 2020. However, above all this is time-consuming. In future, so-called antigen tests could be carried out quickly and as a point-of-care method to facilitate the diagnosis of COVID-19. Changes in serological biomarkers (such as D-dimers, troponin T, CRP) can help to identify patients at risk for a severe COVID-19 course. A routine screening CT thorax to identify COVID-19 pneumonia is currently not recommended by most radiological societies. However, the number of CT examinations is increasing steadily and radiological diagnosis in COVID-19 patients with pulmonary symptoms is becomingmore and more important.